New NICE (UK National Institute for Clinical Excellence) technology appraisal/appeal processes:
This article was originally published in Clinica
Executive Summary
The UK's National Institute for Clinical Excellence (NICE) has today (May 4 2004) published details of its new appraisal and appeal methods and processes. They feature an improved pre-appraisal scoping of the topic; longer appraisal consultation times; more detailed description of the methods for evaluating clinical and economic evidence, incorporating the use of a reference case; and more information on how the cost-effectiveness of technologies is assessed. Appraisals carried out under NICE's latest (9th) agreed wave of topics and those that are yet to be referred in the 10th wave will be appraised under a combination of the existing and new appraisal processes. The new process will come on stream fully for the 11th wave. Guides for use by manufacturers on submitting evidence to NICE will be published later this year.
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.